HOME
FAQs
BLOG
SUBMIT LISTING/OFFER
✕
LIST YOUR INTELLECTUAL PROPERTY
SOPHISTICATED PARTY REQUEST TO LIST IP, COMMISSIONS & TERMS
Effective Date: January 1, 2026
1. Purpose
This Agreement governs the submission of Intellectual Property (IP) to Medical Patents Broker Inc. (“MPB”) from a Sophisticated Party (Business to Business). Submission of IP through this portal is an offer to list the asset; however, MPB reserves the right to decline any listing at its sole discretion. MPB focuses primarily on US Patents and related medical technologies.
2. Seller/Licensor Details
Name of Intellectual Property Owner – Company/Legal Entity
(Required)
Entity Name
Authorized Representative
(Required)
First
Last
Contact Email
(Required)
Address
Street Address
Address Line 2
City
State / Province / Region
ZIP / Postal Code
Country
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos Islands
Colombia
Comoros
Congo
Congo, Democratic Republic of the
Cook Islands
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czechia
Côte d'Ivoire
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Macedonia
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestine, State of
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Romania
Russian Federation
Rwanda
Réunion
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Sweden
Switzerland
Syria Arab Republic
Taiwan
Tajikistan
Tanzania, the United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkmenistan
Turks and Caicos Islands
Tuvalu
Türkiye
US Minor Outlying Islands
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Åland Islands
3. IP Specifics & Disclosure
Patent/Application Numbers
Provide all issued US Patents and published US Patent Applications claiming benefit of the Parent US Patent (the "Related Assets")
(Required)
Invention Title
(Required)
Development Stage
(Required)
Concept
Prototype
Clinical Trials
FDA Approved
Marketed
Competitive Advantage
Describe why this invention is a “Better Improvement” over existing solutions.
4. Commission & Procuring Cause
By submitting this IP, you or the entity you represent, the sophisticated party, expressly agree that MPB is the
Procuring Cause
for any transaction involving this IP with parties introduced by MPB. MPB shall be entitled to commissions on all
Gross Consideration
(including but not limited to: Straight Sales, Upfront Payments, Milestones, and Royalties) for the life of the initial listed Patent(s) and any subsequent Patent claiming the same priority date as the initiating Patent Application’s filing date creating the priority date including but not limited to Continuations, Continuations-in-Part, and Divisionals.
Commission Schedule
• 12% — Straight Sale (Lump Sum/Assignment) • 18% — Hybrid Transaction (Upfront Payment + Future Milestones/Royalties) • 24% — Straight License (Ownership Retained by Seller) • +3% — Additional Charge for Private Listing
5. Commission Obligation
As defined in Section 4.2 of MPB’s
Terms of Service & Conditions
(“Terms”), the obligation to pay these commissions shall continue for as long as the Seller/Licensor (or its successors, assigns, or affiliates) receives monetary payments or Consideration of any kind associated with the submitted IP where MPB was the procuring cause.
6. Authority & Delegation
You represent that you are or represent a Sophisticated Party and have the legal authority to bind the owner of this IP to these
Terms
. You acknowledge MPB’s right to delegate or categorize listings within the
Patent Maestro®, Eclectic
or
Patent Maestro® Vault
portals at its sole discretion to maximize asset visibility/transferabiity.
LEGAL DISCLOSURE
Medical Patents Broker Inc. (“MPB”)
is a transaction facilitator. MPB does not provide legal, financial, or technical advice, nor does it perform patent due diligence, validity analysis, or infringement mapping. MPB relies upon public information and information provided by the Seller; all such information is provided
“as-is”
without warranty of any kind, express or implied. Prospective buyers are responsible for conducting their own independent legal and technical due diligence. MPB’s involvement as a facilitator concludes upon the facilitation of the initial offer or introduction and the handoff the offer to the Seller. Use of this site or documents does not create an attorney-client relationship.
REQUIRED AFFIRMATIONS
By checking the boxes below, I (“the Signer”) represent that I am acting on my own behalf or with the authority to bind the entity I represent (collectively, “the Party”).
1. Status & Role:
(Required)
I confirm the Party is a
Sophisticated Party
(business to business) acting for business purposes. I acknowledge MPB is not an agent, advisor, or fiduciary to the Party.
2. Commission:
(Required)
2. Commission: The Party agrees not to bypass MPB. I acknowledge MPB’s right to commissions on all payments where MPB was the procuring cause.
3. Non-Circumvention:
(Required)
I agree on behalf of the Party that the
24-month non-circumvention obligation
is binding on any of the Parties, parents, subsidiaries, affiliates, see Terms of Service & Conditions.
4. Due Diligence:
(Required)
I acknowledge that MPB does not verify title or validity. All due diligence is the Party’s sole responsibility.
5. Governing Law:
(Required)
The Party agrees to binding arbitration and the exclusive jurisdiction of Kentucky courts, without reference to conflict of laws principles, as set forth in the
Terms of Service & Conditions
.
6. Electronic Signature
(Required)
I have the authority to bind the party. By clicking below, I agree to MPB’s
Terms of Service & Conditions
and MPB’s
Privacy Policy
, and the use of
Cookies
for security and performance.